44.49

0.74% -0.33

Xenon Pharmaceuticals Inc (XENE)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$44.82

Offen:

$45.2

24-Stunden-Volumen:

1.17M

Relative Volume:

1.46

Marktkapitalisierung:

$3.44B

Einnahmen:

$13.17M

Nettoeinkommen (Verlust:

$-199.06M

KGV:

-16.24

EPS:

-2.74

Netto-Cashflow:

$-156.53M

1W Leistung:

-0.78%

1M Leistung:

+3.75%

6M Leistung:

+33.32%

1J Leistung:

+10.75%

1-Tages-Spanne:

$43.20

$45.23

1-Wochen-Bereich:

$43.20

$46.36

52-Wochen-Spanne:

$26.74

$46.60

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Firmenname

Xenon Pharmaceuticals Inc

Sektor

Healthcare (1131)

Branche

Biotechnology (631)

Telefon

(604) 484-3300

Adresse

200 - 3650 GILMORE WAY, BURNABY

Mitarbeiter

327

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

XENE's Discussions on Twitter

Vergleichen Sie XENE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XENE Xenon Pharmaceuticals Inc	44.49	3.46B	13.17M	-199.06M	-156.53M	-2.74
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-03	Fortgesetzt	Wells Fargo	Overweight
2025-05-07	Eingeleitet	Chardan Capital Markets	Buy
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-10-01	Eingeleitet	H.C. Wainwright	Buy
2024-01-04	Eingeleitet	Citigroup	Buy
2023-12-08	Eingeleitet	Robert W. Baird	Outperform
2023-10-24	Fortgesetzt	Cantor Fitzgerald	Overweight
2023-04-25	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-14	Eingeleitet	Goldman	Buy
2022-12-12	Eingeleitet	Cowen	Outperform
2022-11-28	Eingeleitet	Wells Fargo	Overweight
2022-10-19	Eingeleitet	Raymond James	Outperform
2022-08-29	Eingeleitet	BofA Securities	Buy
2022-07-21	Eingeleitet	JP Morgan	Overweight
2021-10-28	Eingeleitet	RBC Capital Mkts	Outperform
2020-10-02	Eingeleitet	SVB Leerink	Outperform
2020-07-21	Eingeleitet	Needham	Buy
2020-06-01	Fortgesetzt	Jefferies	Buy
2020-03-25	Eingeleitet	Wedbush	Outperform
2020-01-08	Eingeleitet	William Blair	Outperform
2019-09-20	Eingeleitet	Guggenheim	Buy
2018-08-08	Bestätigt	Stifel	Buy
2017-03-13	Eingeleitet	Jefferies	Buy
2016-10-21	Eingeleitet	Stifel	Buy
2016-09-26	Eingeleitet	Guggenheim	Buy
2016-04-14	Bestätigt	Jefferies	Buy
2015-10-30	Fortgesetzt	Jefferies	Buy
2014-12-02	Eingeleitet	Canaccord Genuity	Buy

Alle ansehen

Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten

Jan 02, 2026

Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - MarketBeat

Jan 02, 2026

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World

Jan 02, 2026

Jan 01, 2026

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Jan 01, 2026

Dec 31, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat

Dec 31, 2025

Dec 30, 2025

Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail

Dec 30, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail

Dec 30, 2025

Dec 29, 2025

Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq

Dec 29, 2025

Harbor Capital Advisors Inc. Has $450,000 Holdings in Xenon Pharmaceuticals Inc. $XENE - Defense World

Dec 29, 2025

Dec 28, 2025

Xenon announces new data on 48-month azetukalner OLE study data - MSN

Dec 28, 2025

Dec 26, 2025

Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com Canada

Dec 26, 2025

Biohaven Misses The Mark In Depression Trial, Stock Falls - Sahm

Dec 26, 2025

Dec 25, 2025

Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat

Dec 25, 2025

Dec 23, 2025

Why (XENE) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Dec 23, 2025

Dec 21, 2025

Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatMarket Performance Summary & Stepwise Swing Trade Plans - bolumsonucanavari.com

Dec 21, 2025

Dec 20, 2025

Pullback Watch: How rising interest rates impact Xenon Pharmaceuticals Inc. stockMarket Sentiment Report & Growth Focused Stock Pick Reports - Улправда

Dec 20, 2025

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Dec 20, 2025

Dec 19, 2025

Returns Recap: Why Xenon Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Capital Efficient Trading Techniques - Улправда

Dec 19, 2025

Will Xenon Pharmaceuticals Inc. stock outperform tech sector in 20252025 Price Targets & Long Hold Capital Preservation Plans - Улправда

Dec 19, 2025

Can Xenon Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Precise Entry and Exit Recommendations - Улправда

Dec 19, 2025

Is Xenon Pharmaceuticals Inc. stock attractive for passive investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда

Dec 19, 2025

Dec 18, 2025

Why Xenon Pharmaceuticals Inc. stock remains undervalued2025 Market Overview & Fast Entry High Yield Stock Tips - Улправда

Dec 18, 2025

How rising interest rates impact Xenon Pharmaceuticals Inc. stockForecast Cut & High Conviction Buy Zone Alerts - Улправда

Dec 18, 2025

Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha

Dec 18, 2025

Dec 13, 2025